The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …
New perspectives on the basal forebrain cholinergic system in Alzheimer's disease
The basal forebrain cholinergic system (BFCS) has long been implicated in age-related
cognitive changes and the pathophysiology of Alzheimer's disease (AD). Limitations of …
cognitive changes and the pathophysiology of Alzheimer's disease (AD). Limitations of …
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
Abstract The endosome-associated GTPase Rab5 is a central player in the molecular
mechanisms leading to degeneration of basal forebrain cholinergic neurons (BFCN), a long …
mechanisms leading to degeneration of basal forebrain cholinergic neurons (BFCN), a long …
[HTML][HTML] Structural Degeneration of the Nucleus basalis of Meynert in Mild Cognitive Impairment and Alzheimer's Disease–Evidence from an MRI-based Meta-Analysis
M Mieling, H Meier, N Bunzeck - Neuroscience & Biobehavioral Reviews, 2023 - Elsevier
Recent models of Alzheimer's Disease (AD) suggest that neuropathological changes of the
medial temporal lobe, especially entorhinal cortex, are preceded by degenerations of the …
medial temporal lobe, especially entorhinal cortex, are preceded by degenerations of the …
Cholinergic white matter pathways along the Alzheimer's disease continuum
Previous studies have shown that the cholinergic nucleus basalis of Meynert and its white
matter projections are affected in Alzheimer's disease dementia and mild cognitive …
matter projections are affected in Alzheimer's disease dementia and mild cognitive …
State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities
Primary prevention trials have shifted their focus to the earliest stages of Alzheimer's disease
(AD). Autopsy data indicates that the neuromodulatory subcortical systems'(NSS) nuclei are …
(AD). Autopsy data indicates that the neuromodulatory subcortical systems'(NSS) nuclei are …
Improving anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's disease: are irreversible inhibitors the future?
DE Moss - International journal of molecular sciences, 2020 - mdpi.com
Decades of research have produced no effective method to prevent, delay the onset, or slow
the progression of Alzheimer's disease (AD). In contrast to these failures …
the progression of Alzheimer's disease (AD). In contrast to these failures …
Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases
Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …
treatment of Alzheimer's disease (AD) and show significant positive effects in …
Grey matter loss at different stages of cognitive decline: A role for the thalamus in develo** Alzheimer's disease
Background: Alzheimer's disease (AD) is characterized by cognitive impairment and large
loss of grey matter volume and is the most prevalent form of dementia worldwide. Mild …
loss of grey matter volume and is the most prevalent form of dementia worldwide. Mild …
REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals
Background Rapid-eye movement (REM) sleep highly depends on the activity of cholinergic
basal forebrain (BF) neurons and is reduced in Alzheimer's disease. Here, we investigated …
basal forebrain (BF) neurons and is reduced in Alzheimer's disease. Here, we investigated …